

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington DC 20551-0001, not later than June 2, 2022.

*A. Federal Reserve Bank of Chicago* (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414:

1. *The David C. Neuhaus Bank Stock Revocable Trust, Fairfax, Iowa; Laurie Neuhaus, as trustee, Amana, Iowa; Patrick Slater, Lois E. Slater, John C. Slater, John E. Neuhaus and Carla A. Neuhaus, all of Cedar Rapids, Iowa; the John D. Lefebure 2010 Revocable Trust, John D. Lefebure, as trustee, both of Fairfax, Iowa; James Neuhaus, Amana, Iowa; and David J. Slater, Lakewood, Colorado;* to become members of the Neuhaus Family Control Group, a group acting in concert, to retain voting shares of Vanderbilt Holding Company, Inc., and thereby indirectly retain voting shares of Fairfax State Savings Bank, both of Fairfax, Iowa. Additionally, Patrick Slater to acquire additional voting shares of Vanderbilt Holding Company, Inc., and thereby indirectly acquire voting shares of Fairfax State Savings Bank.

Board of Governors of the Federal Reserve System.

**Margaret M. Shanks,**

*Deputy Secretary of the Board.*

[FR Doc. 2022-10710 Filed 5-17-22; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Healthcare Research and Quality

#### Supplemental Evidence and Data Request on Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings: Systematic Review Update

**AGENCY:** Agency for Healthcare Research and Quality (AHRQ), HHS.

**ACTION:** Request for supplemental evidence and data submissions.

**SUMMARY:** The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review on *Pharmacotherapy for Adults with Alcohol-Use Disorders in Outpatient Settings: Systematic Review Update*, which is currently being conducted by the AHRQ's Evidence-based Practice Centers (EPC) Program. Access to published and unpublished pertinent scientific information will improve the quality of this review.

**DATES:** *Submission Deadline* on or before June 17, 2022.

**ADDRESSES:**

*Email submissions:* [epc@ahrq.hhs.gov](mailto:epc@ahrq.hhs.gov).

*Print submissions:*

Mailing Address: Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857

Shipping Address (FedEx, UPS, etc.): Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD 20857

**FOR FURTHER INFORMATION CONTACT:** Jenae Benns, Telephone: 301-427-1496 or Email: [epc@ahrq.hhs.gov](mailto:epc@ahrq.hhs.gov).

**SUPPLEMENTARY INFORMATION:** The Agency for Healthcare Research and Quality has commissioned the Evidence-based Practice Centers (EPC) Program to complete a review of the evidence for *Pharmacotherapy for Adults with Alcohol-Use Disorders in Outpatient Settings: Systematic Review Update*. AHRQ is conducting this systematic review pursuant to Section 902 of the Public Health Service Act, 42 U.S.C. 299a.

The EPC Program is dedicated to identifying as many studies as possible that are relevant to the questions for

each of its reviews. In order to do so, we are supplementing the usual manual and electronic database searches of the literature by requesting information from the public (e.g., details of studies conducted). We are looking for studies that report on Pharmacotherapy for Adults with Alcohol-Use Disorders in Outpatient Settings: Systematic Review Update, including those that describe adverse events. The entire research protocol is available online at: <https://effectivehealthcare.ahrq.gov/products/alcohol-misuse-drug-therapy/protocol>.

This is to notify the public that the EPC Program would find the following information on Pharmacotherapy for Adults with Alcohol-Use Disorders in Outpatient Settings: Systematic Review Update helpful:

- A list of completed studies that your organization has sponsored for this indication. In the list, please *indicate whether results are available on ClinicalTrials.gov along with the ClinicalTrials.gov trial number.*
  - *For completed studies that do not have results on ClinicalTrials.gov, a summary, including the following elements: Study number, study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, primary and secondary outcomes, baseline characteristics, number of patients screened/eligible/enrolled/lost to follow-up/withdrawn/analyzed, effectiveness/efficacy, and safety results.*

- *A list of ongoing studies that your organization has sponsored for this indication.* In the list, please provide the *ClinicalTrials.gov* trial number or, if the trial is not registered, the protocol for the study including a study number, the study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, and primary and secondary outcomes.

- Description of whether the above studies constitute *ALL Phase II and above clinical trials* sponsored by your organization for this indication and an index outlining the relevant information in each submitted file.

Your contribution is very beneficial to the Program. Materials submitted must be publicly available or able to be made public. Materials that are considered confidential; marketing materials; study types not included in the review; or information on indications not included in the review cannot be used by the EPC Program. This is a voluntary request for information, and all costs for complying with this request must be borne by the submitter.

The draft of this review will be posted on AHRQ's EPC Program website and

available for public comment for a period of 4 weeks. If you would like to be notified when the draft is posted, please sign up for the email list at: <https://www.effectivehealthcare.ahrq.gov/email-updates>.

The systematic review will answer the questions below. This information is provided as background and AHRQ is not requesting that the public provide answers to these questions.

### Key Questions (KQ)

**KQ 1a:** Which medications are efficacious for improving consumption outcomes for adults with alcohol-use disorders in outpatient settings?

**KQ 1b:** How do medications for adults with alcohol-use disorders compare for improving consumption outcomes in outpatient settings?

**KQ 2a:** Which medications are efficacious for improving health outcomes (including functioning and quality-of-life outcomes) for adults with alcohol-use disorders in outpatient settings?

**KQ 2b:** How do medications for adults with alcohol-use disorders compare for improving health outcomes (including functioning and quality-of-life outcomes) in outpatient settings?

**KQ 3a:** What adverse effects are associated with medications for adults with alcohol-use disorders in outpatient settings?

**KQ 3b:** How do medications for adults with alcohol-use disorders compare for adverse effects in outpatient settings?

**KQ 4:** Are medications for treating adults with alcohol-use disorders effective in primary care settings?

**KQ 5:** Are any of the medications more or less effective than other medications for older adults, younger adults, smokers, or those with co-occurring disorders?

### PICOTS (Populations, Interventions, Comparators, Outcomes, Timing, and Setting)

#### • Population(s)

○ Adults (age 18 years or older) with alcohol-use disorders.

#### • Interventions

○ Pharmacotherapy for relapse prevention. This includes:

■ Medications approved by FDA for treating alcohol dependence:

- Acamprosate
- disulfiram
- naltrexone (oral or injectable)

■ Certain medications in use off label that are available in the United States:

- Baclofen
- gabapentin
- ondansetron

- topiramate
- prazosin
- varenicline

○ Studies evaluating pharmacotherapy that used co-interventions with other treatments for AUDs (e.g., behavioral counseling, cognitive behavioral therapy, motivational enhancement therapy, psychosocial treatments, or self-help such as 12-step programs [e.g., Alcoholics Anonymous]) will be eligible for inclusion, as long as they meet other inclusion/exclusion criteria.

○ This review will not include pharmacotherapy for alcohol withdrawal.

#### • Comparators

○ Studies must compare one of the medications listed above with placebo or another eligible medication.

#### • Outcomes

○ Consumption outcomes:

- Abstinence/any drinking
  - rates of continuous abstinence
  - percentage of days abstinent
  - time to first drink/lapse
  - time to heavy drinking/relapse
- reduction in alcohol consumption
  - number of heavy drinking days
  - percentage of subjects with no heavy drinking days
  - number of drinking days
  - drinks per drinking day
  - drinks per week

○ Health outcomes:

- Accidents
- injuries
- quality of life
- function
- mortality
  - Adverse effects of intervention(s):
- Withdrawals due to adverse events
- nausea/vomiting
- diarrhea
- anorexia
- alptitions
- headache
- dizziness
- cognitive dysfunction
- taste abnormalities
- paresthesias (numbness, tingling)
- metabolic acidosis
- glaucoma
- vision changes
- suicidal ideation
- insomnia
- anxiety
- rash
- tiredness
- weakness
- constipation

#### • Timing

○ Studies with at least 12 weeks of planned pharmacologic treatment and

followup from the time of medication initiation.

#### • Setting

○ Outpatient healthcare settings; KQ 4 applies to primary care settings only (i.e., internal medicine, family medicine, obstetrics/gynecology, or college and university health clinics).

Dated: May 12, 2022.

**Marquita Cullom,**

*Associate Director.*

[FR Doc. 2022-10614 Filed 5-17-22; 8:45 am]

**BILLING CODE 4160-90-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Submission for OMB Review; Plan for Foster Care and Adoption Assistance—Title IV–E (OMB #0970–0433)

**AGENCY:** Children's Bureau, Administration for Children and Families, HHS.

**ACTION:** Request for public comment.

**SUMMARY:** The Children's Bureau (CB), Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS), is requesting a 3-year extension of the Plan for Foster Care and Adoption Assistance—Title IV–E, (OMB#: 0970–0433, expiration 11/30/2022). This plan also incorporates the plan requirements for the optional Guardianship Assistance program, the Title IV–E Prevention Services plan and the Title IV–E Kinship Navigator program. There are no changes requested to the form.

**DATES:** *Comments due within 30 days of publication.* OMB must make a decision about the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication.

**ADDRESSES:** Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain). Find this particular information collection by selecting "Currently under 30-day Review—Open for Public Comments" or by using the search function. You can also obtain copies of the proposed collection of information by emailing [infocollection@acf.hhs.gov](mailto:infocollection@acf.hhs.gov). Identify all emailed